⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Floratek Pharma SA and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Floratek Pharma SA
↗Belmont-sur-Lausanne, Switzerland
Floratek Pharma is a Swiss-based, privately owned pharmaceutical company focused on drug discovery and preclinical development. The company specializes in optimizing natural compounds, particularly flavonoids, to create novel small-molecule therapeutics for oncology, neurodegenerative disorders, and anti-aging applications.
Leveraging artificial intelligence and computational modeling, Floratek focuses on mitochondrial modulation and metabolic differences between healthy and cancerous cells. The company operates as a research-intensive entity with a lean team, collaborating with academic and research institutions to advance its pipeline of proprietary compounds.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2015
Ownership:private
Status:operating
FUNDING
Stage:Private
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical
Modalities:Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Institute of Oncology Research (IOR), Oncolines BV, Symeres BV, Pelago Bioscience AB
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Dan F. Stoicescu - CEO & CSO
Paulina Biniecka - Associate Director
Scientific Founders:Dan F. Stoicescu
LINKS
Website:floratekpharma.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Floratek Pharma SA. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.